M&A / Deals Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novo’s CEO champions “record-breaking start” for Wegovy pill in US marketNext: Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
